Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.
Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.
The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.